NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors Abstract #1676

Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Aim(s): EORTC questionnaires C30 and GINET21 were used to determine the impact of treatment on health-related quality of life (HRQoL).
Materials and methods: Patients completed the two QoL questionnaires at baseline and every 12 weeks until disease progression. Individual changes from baseline scores were assessed. Deteriorations/improvements were considered clinically significant when ≥10 points.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Jonathan Strosberg

To read results and conclusion, please login ...

Further abstracts you may be interested in

#854 Scoping Study on Quality of Life (QL) in Patients (pts) with Neuroendoncrine Tumors (NET) of the Digestive Tract in Argentina: Preliminary Results
Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: RN Gladys Grance
#1062 United Kingdom NET Patient Survey Quality of Life Results
Introduction: QoL is of paramount importance in patients diagnosed with cancer, this is especially true in patients with NETs since the median survival from diagnosis is 7 years.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Raj Srirajaskanthan
Keywords: Quality of life, NET
#1508 NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results
Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Jonathan Strosberg
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, ...
Keywords: Lutathera, PRRT, NET
#1825 The Effect of PRRT on Health-Related Quality of Life in NET Patients: A Prospective Study
Introduction: Neuroendocrine tumour (NET) patients experience poor health-related quality of life (HRQOL). Peptide receptor radionuclide therapy (PRRT) is a promising treatment option although its impact on HRQOL is not well understood.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dainik Patel
#2038 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors
Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p<0.0001) between the treatment arms.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Jonathan Strosberg
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, ...